### UNITED THERAPEUTICS CORP Form SC 13G/A February 14, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

United Therapeutics Corporation				
(Name of Issuer)				
Common Stock, \$0.01 par value				
(Title of Class of Securities)				
91307C102				
(CUSIP Number)				
December 31, 2006				
(Date of Event Which Requires Filing of this Statement)				
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:				
[_] Rule 13d-1(b)				
[X] Rule 13d-1(c)				
[_] Rule 13d-1(d)				
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which				

person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 91307C102

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)	
	Shumway Capital Partners LLC	
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTION (a) (b)	[X] [_] NS)
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION	
	Delaware	
NUMBE	ER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	
5.	SOLE VOTING POWER	
	0	
6.	SHARED VOTING POWER	
	666,599	
7.	SOLE DISPOSITIVE POWER	
	0	
8.	SHARED DISPOSITIVE POWER	
	666,599	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	666,599	
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
		[_]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9	
	2.90%	
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)	
	IA, OO	

CUSIP No. 91307C102

1.	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
	Chris W. Shumway
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)  (a) [_]  (b) [X]
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION
	United States of America
NUMBE	ER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.	SOLE VOTING POWER
	0
6.	SHARED VOTING POWER
	666,599
7.	SOLE DISPOSITIVE POWER
	0
8.	SHARED DISPOSITIVE POWER
	666,599
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	666,599
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
	[_]
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
	2.90%
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
	IN
CUSI	P No. 91307C102

Item 1(a). Name of Issuer:

			United Therapeutics Corporation					
	(b)		Address of Issuer's Principal Executive Offices:					
			1110 Spring Street Silver Spring, Maryland 20910 United States					
Item	2(a)		Name of Persons Filing:					
			Shumway Capital Partners LLC Chris W. Shumway					
	(b)		Address of Principal Business Office, or if None, Residence:					
			Shumway Capital Partners LLC One Fawcett Place Greenwich, CT 06830					
			Chris W. Shumway c/o Shumway Capital Partners LLC One Fawcett Place Greenwich, CT 06830					
	(C)		Citizenship:					
	(0)		Shumway Capital Partners LLC - Delaware Chris W. Shumway - United States of America					
	(d)		Title of Class of Securities:					
			Common Stock, \$0.01 par value					
	(e)		CUSIP Number:					
			91307C102					
Item	3.		If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a:					
	(a)	[_]	Broker or dealer registered under Section 15 of the Exchange Act $(15\ \text{U.S.C.}\ 78\text{c})$ .					
	(b)	[_]	Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).					
	(c)	[_]	Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).					
	(d)	[_]	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).					

	(e)	[_]	An investment adviser in accordance with s.240.13d-1(b)	(1)(ii)(E);
	(f)	[_]	An employee benefit plan or endowment fund in accord $s.240.13d-1$ (b) (1) (ii) (F);	dance with
	(g)	[_]	A parent holding company or control person in accord Rule 13d-1(b)(1)(ii)(G);	dance with
	(h)	[_]	A savings association as defined in Section 3(b) of t Deposit Insurance Act (12 U.S.C.1813);	the Federal
	(i)	[_]	A church plan that is excluded from the definit investment company under Section 3(c)(14) of the Company Act of 1940 (15 U.S.C. 80a-3);	
	(j)	[_]	Group, in accordance with $s.240.13d-1(b)(1)(ii)(J)$ .	
Item	4.	Owner	eship.	
perce			the following information regarding the aggregate the class of securities of the issuer identified in Ite	
	(a)	Amou	unt beneficially owned:	
			Shumway Capital Partners LLC - 666,599 Chris W. Shumway - 666,599	
(b)		Perce	ent of class:	
			Shumway Capital Partners LLC - 2.90% Chris W. Shumway - 2.90%	
	(c)	Numk	per of shares as to which the person has:	
Shumv	vay (	Capita	al Partners LLC	
		(i)	Sole power to vote or to direct the vote	0,
		(ii)	Shared power to vote or to direct the vote	666,599
		(iii	i) Sole power to dispose or to direct the disposition of	0,
		(iv)	Shared power to dispose or to direct the disposition of	666 <b>,</b> 599
Chris	s W.	Shumv	vay 	
	(c)	Numk	per of shares as to which the person has:	
		(i)	Sole power to vote or to direct the vote	0
		(ii)	Shared power to vote or to direct the vote	666,599

----,

(:	iii)	Sole power to dispose or to direct the disposition of	0
(.	iv)	Shared power to dispose or to direct the disposition of	666,599
If this hereof the	s sta repor	nip of Five Percent or Less of a Class.  Attended to report the fact the string person has ceased to be the beneficial the class of securities, check the following	l owner of more than
If any direct the securities, item and, is person should company regarders.	otherecei a st f suc ld be	nip of More Than Five Percent on Behalf of a person is known to have the right to receipt of dividends from, or the proceeds from tatement to that effect should be included to interest relates to more than five percent identified. A listing of the shareholders ared under the Investment Company Act of 1940 of the plan, pension fund or endowment fund is	eive or the power to the sale of, such in response to this nt of the class, such s of an investment 0 or the beneficiaries
		N/A 	
Sec Pe:	curit rson.	fication and Classification of the Subsidia by Being Reported on by the Parent Holdin t holding company or Control person has file	ng Company or Control
pursuant to exhibit star subsidiary. schedule pur	Rule ting If rsuar	the 13d-1(b)(1)(ii)(G), so indicate under Item the identity and the Item 3 classification a parent holding company or control person at to Rule 13d-1(c) or Rule 13d-1(d), attackion of the relevant subsidiary.	m 3(g) and attach an of the relevant has filed this
		N/A	

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to s.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to s.240.13d-1(c) or s.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

 IV/ A			
N / A			

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A ------

Item 10. Certification.

By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

#### SIGNATURE

After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

February 14, 2007

(Date)

Shumway Capital Partners LLC\*

By: /s/ Chris W. Shumway

Name: Chris W. Shumway

Title: Managing Member

\_\_/s/ Chris W. Shumway\*\_\_\_\_\_\_

Chris W. Shumway

\* The Reporting Persons disclaim beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

Exhibit A

#### AGREEMENT

The undersigned agree that this Schedule 13G dated February 14, 2007 relating to the Common Stock, \$0.01 par value of United Therapeutics Corporation shall be filed on behalf of the undersigned.

Shumway Capital Partners LLC\*

By: /s/ Chris W. Shumway\_\_\_\_\_\_

Name: Chris W. Shumway

Title: Managing Member

\_\_\_/s/ Chris W. Shumway\*\_\_\_\_\_\_

Chris W. Shumway

SK 03971 0001 747004